NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

Telemedicine trial results to be presented at ACC 24

EditorNatashya Angelica
Published 01/02/2024, 08:14
© Reuters.
SHLTN
-

TEL AVIV, Israel & ZURICH & NEW YORK - SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN), a company specializing in advanced personal telemedicine solutions, has announced that the TELE-ACS clinical trial results will be showcased at the American College of Cardiology's 24th Annual Scientific Session & Expo (ACC 24). The trial, a collaboration with Imperial College London, examines the effectiveness of remote cardiovascular patient assessment post-acute coronary syndrome using SHL's SmartHeart® technology.

The presentation, scheduled for April 6, 2024, will reveal the full findings of the TELE-ACS trial, a study that could mark a significant advancement in telemedicine for cardiovascular care. The trial focused on high-risk patients following an acute coronary syndrome and utilized SHL's SmartHeart® 12-lead ECG technology for at-home monitoring.

Erez Nachtomy, CEO of SHL Telemedicine, expressed pride in the trial's selection for ACC 24, recognizing it as a testament to the diligent efforts of the team at Imperial College London. The results, which are currently embargoed, will be shared with the global cardiology community during the conference.

SHL Telemedicine, listed on both the SIX Swiss Exchange and the Nasdaq Stock Exchange, provides telemedicine systems and medical call center services, concentrating on cardiovascular and related diseases. The company offers its services and devices to subscribers through telephonic and internet communication technologies.

The announcement is based on a press release statement, and the information is expected to be of interest to investors and the medical community, as it may influence the adoption and integration of telemedicine technologies in cardiovascular patient care. The ACC 24 presentation will provide an opportunity for attendees to gain insights into the potential benefits and applications of remote monitoring for patients with cardiovascular conditions.

InvestingPro Insights

As SHL Telemedicine Ltd. (NASDAQ: SHLTN) prepares to reveal the TELE-ACS clinical trial results, investors and stakeholders are closely observing the company's financial health and market performance. According to the latest data from InvestingPro, SHL Telemedicine holds a market capitalization of 110.19 million USD, indicating its size and significance in the telemedicine industry. Despite recent challenges, as the stock has fared poorly over the last month with a 16.55% drop, SHL Telemedicine's liquid assets exceed its short-term obligations, which may provide some financial stability for the company.

InvestingPro Tips suggest that SHL Telemedicine is trading near its 52-week low and operates with a moderate level of debt, which could present a buying opportunity for investors who believe in the company’s long-term prospects. Notably, the firm has not been profitable over the last twelve months, and it does not pay a dividend to shareholders, indicating that potential investors should have a tolerance for risk and a focus on growth potential.

For those interested in a deeper analysis, InvestingPro+ offers additional tips on SHL Telemedicine, and with the current special New Year sale, subscriptions are now available at up to 50% off. To further enhance this offer, use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year InvestingPro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.